Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer (NCT04721132)
An Open-Label, Phase II, Pre-Operative Study of Atezolizumab Plus Bevacizumab for Resectable Hepatocellular Carcinoma
🩺 Plain-English Summary (8th-Grade Level)
This phase II trial studies the effect of atezolizumab and bevacizumab before surgery in treating patients with liver cancer that can be removed by surgery (resectable). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Bevacizumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Giving the combination of atezolizumab and bevacizumab may help to prevent liver cancer from returning after surgery.
Who can join: Review the eligibility criteria below.
Location: Houston Methodist Hospital — Houston, Texas
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (2 Sites)
- Houston Methodist Hospital — Houston, Texas
- M D Anderson Cancer Center — Houston, Texas
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Resectable Hepatocellular Carcinoma
- SIRT With Tremelimumab and Durvalumab for Resectable HCC — Los Angeles, California
- Detection of Plasma DNA Methylation in Peripheral Blood From Patients With Resectable Liver Cancer — Rochester, Minnesota
- THIO and Cadonilimab in Resectable Hepatocellular Carcinoma — Dallas, Texas
Explore by condition: All Resectable Hepatocellular Carcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.